Navigation Links
Sigma-Aldrich Corporation's Sigma Life Science Business to Distribute Worldwide Olink Bioscience's Protein Interaction Analysis Technology
Date:2/12/2013

g genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 38 countries and has nearly 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range of critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co, LLC registered in the US and other countries. CompoZr, MISSION and Prestige are registered trademarks of Sigma-Aldrich Co. LLC. Duolink and PLA are registered trademarks of Olink AB.


'/>"/>
SOURCE Sigma-Aldrich Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sigma-Aldrich Reports Record Full Year 2012 Results. Reports Q4 2012 Diluted EPS Of $0.96. Q4 2012 Sales Increased 7%. Full Year 2012 Adjusted Diluted EPS Was $3.85. Expects Full Year 2013 Adjusted Diluted EPS To Increase To $4.10 - $4.20.
2. Sigma-Aldrich Aligns Into Three New Market-Focused Business Units
3. Sigma-Aldrich (NASDAQ: SIAL) Declares $0.20 Quarterly Dividend
4. Sigma-Aldrich Enhances Customer Focus in China - Unveils Dynamic New Website and Expands Product Offering Through Vetec Brand
5. Sigma-Aldrich Corporation To Present At Upcoming Investor Conferences
6. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
7. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
8. Henry Schein Ranks #303 In 2012 FORTUNE 500® Ranking Of Americas Largest Corporations
9. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
10. NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy
11. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today ... Agreements with Dexcom, Inc. to allow the integration ... Dexcom G5 and G6 continuous glucose monitoring ("CGM") ... platform with Dexcom,s future CGM systems is an ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... (Nasdaq: DCTH ) will host a live webcast ... meeting on May 23, 2012 at 10:00 a.m ET at ... commence at approximately 10:15 a.m ET. To listen ... during or after the event, please visit the Investor Relations ...
... May 21, 2012 InfuSystem Holdings, Inc. (NYSE MKT: ... infusion pumps and related services, today announced that it ... notification to NYSE Amex of the "record date" for ... April 30, 2012 the record date for the Company,s ...
Cached Medicine Technology:Delcath to Webcast Management's Presentation at Annual Meeting of Stockholders 2Delcath to Webcast Management's Presentation at Annual Meeting of Stockholders 3InfuSystem Holdings, Inc. Receives Letter From NYSE MKT Regarding Timely Notice Of Record Date For 2012 Annual Meeting Of Stockholders 2
(Date:7/30/2015)... Austin, Texas (PRWEB) , ... July 30, 2015 ... ... Critical Path Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that ... Dyslipidemia have been published for use on the CDISC website . These ...
(Date:7/30/2015)... ... 2015 , ... Women's dating coach Simone Myers has just ... interested in improving their love lives using specific "lines" designed to trigger powerful ... public early this morning, has drawn praise from several dating and relationship advice ...
(Date:7/30/2015)... ... July 30, 2015 , ... Mullin/Ashley Associates, Inc. , ... awards in the Service Industry Advertising Awards 12th annual national competition. , ... Corporation and University of Maryland Shore Regional Health. , A Gold Award was ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... monthly Biz Report, which takes a look at small, medium, and large businesses ... a business expert, conducted the business review and shared with viewers how DevExpress ...
(Date:7/30/2015)... ... 2015 , ... The need for accessibility is never greater than when we ... as well as visiting friends and family during these critical moments, hospitals around the ... - powered by ChargeItSpot , a Philadelphia-based startup that recently secured a $4M ...
Breaking Medicine News(10 mins):Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2
... RESEARCH TRIANGLE PARK, N.C., Sept. 21 GlaxoSmithKline ... funding accredited, continuing medical education (CME) for healthcare professionals to ... in 2010, GSK will raise the bar and fund only ... gaps in patient care, and that demonstrate support for the ...
... , , BRISTOL, Tenn., ... (APF) says economic pain from the recession is contributing to acute ... Pharmaceuticals(R), Inc. has launched a consumer education initiative with RealAge.com to ... of the back and other areas. , , ...
... , ST. LOUIS, Sept. 21 ... to Perrigo Company (Nasdaq: PRGO ) of KV,s first-to-file ... and Drug Administration for a generic equivalent version of GlaxoSmithKline,s Duac(R) ... the transaction, KV will receive $14 million from Perrigo at closing ...
... isn,t a given, researchers find, , MONDAY, Sept. 21 (HealthDay ... they age, but researchers now suspect that,s not the case. ... Neuropsychology examines long-term Dutch research into aging brains, which ... the brain. , The researchers looked at data from ...
... , , , ... business of Motorola, Inc. (NYSE: ... and Motorola channel partner, has deployed its 802.11n wireless LAN ... a community hospital located in Ludington, Mich. , , ...
... , , , TROY, Mich., Sept. 21 ... will present an overview of the Company at the following conferences: , , ... Wednesday, September 23, 2009 , 10:00 a.m. ( ET) , Grand Hyatt, New ... , , Tuesday, September 29, 2009 , 9:00 a.m. ...
Cached Medicine News:Health News:GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care 2Health News:GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care 3Health News:With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals(R), Inc. and RealAge.com Launch Effort to Educate Americans on Prevention and Treatment 2Health News:With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals(R), Inc. and RealAge.com Launch Effort to Educate Americans on Prevention and Treatment 3Health News:With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals(R), Inc. and RealAge.com Launch Effort to Educate Americans on Prevention and Treatment 4Health News:With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals(R), Inc. and RealAge.com Launch Effort to Educate Americans on Prevention and Treatment 5Health News:With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals(R), Inc. and RealAge.com Launch Effort to Educate Americans on Prevention and Treatment 6Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 2Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 3Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 4Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 5Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 6Health News:Motorola's 802.11n Wireless LAN Solution Improves Patient Care and Wireless Security at Memorial Medical Center of Western Michigan 2Health News:Motorola's 802.11n Wireless LAN Solution Improves Patient Care and Wireless Security at Memorial Medical Center of Western Michigan 3Health News:Motorola's 802.11n Wireless LAN Solution Improves Patient Care and Wireless Security at Memorial Medical Center of Western Michigan 4Health News:Motorola's 802.11n Wireless LAN Solution Improves Patient Care and Wireless Security at Memorial Medical Center of Western Michigan 5Health News:Somanetics Corporation To Present at UBS Global Life Sciences Conference and Maxim Group Growth Conference 2
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
Multiple Modulation Phaco (MMP) programmability with eight surgeon settings for maximum versatility. The combination of the peristaltic power balanced pump and the piezoelectric handpiece results in ...
Phaco-emulsification systems CV series...
... The SIStem (Solutions ... departs from the traditional. ... perspectives in phaco, with ... totally unique fluidics module, ...
Medicine Products: